Stocks to watch: Tata Power, HCL Tech, NMDC, Shilpa Medicare among shares to remain in focus today
Following approval from the Republic of the Philippines Securities and Exchange Commission, the company's step-down ...
AstraZeneca reports positive outcomes from trial of Imfinzi
AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
Stocks To Watch Today, March 10: Rice, R Infra, Voda Idea, IndusInd, Gensol
Tata Power, Nazara Tech, Lupin, Biocon, JSW Steel, Shilpa Medicare, and Oriental Rail are some other stocks to watch today, ...
Stocks to Watch Today: Lupin, Tata Power, Nazara Tech, Shilpa Medicare, GMR Airports, IRB Infra, Railtel, Shyam Metalics in focus on 10 March
Stocks like India Pesticides, HFCL, NDR Auto Components, JSW Steel, GR Infraprojects, Biocon, Oil and Natural Gas Corporation ...
CURE5d
Imfinzi Plus Chemo May Improve Event-Free Survival in Gastric, GEJ Cancers
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
Medical Dialogues5d
AstraZeneca Pharma India secures CDSCO nod to import, sell Durvalumab for small cell lung cancer
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
BioSpace6d
AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
Health And Pharma6d
Imfinzi Shows Significant Survival Benefit in Gastric and GEJ Cancer Treatment
The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
MPR6d
Durvalumab Plus FLOT Improves Event Free Survival in Gastric/GEJ Cancer
Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...
Targeted Oncology6d
Durvalumab Plus Chemotherapy Boosts EFS in Gastric/GEJ Cancer
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
EuropaWire6d
MATTERHORN Trial Shows Perioperative Immunotherapy Significantly Enhances Survival in Gastric and GEJ Cancer Patients
The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...